T. Rowe Price Associates’s Lipocine LPCN Stock Holding History

T. Rowe Price Associates’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32K	Buy	+12,266	New	+$29.5K	﹤0.01%	3208
2023 Q2	–	Sell	-10,271	Closed	-$56K	–	2916
2023 Q1	$56K	Sell	10,271 -591	-5%	-$4.57K	﹤0.01%	2777
2022 Q4	$71K	Hold	10,862	–	–	﹤0.01%	2768
2022 Q3	$84K	Hold	10,862	–	–	﹤0.01%	2762
2022 Q2	$148K	Hold	10,862	–	–	﹤0.01%	2672
2022 Q1	$253K	Hold	10,862	–	–	﹤0.01%	2618
2021 Q4	$183K	Buy	10,862 +282	+3%	+$5.24K	﹤0.01%	2780
2021 Q3	$196K	Buy	10,580 +5,329	+101%	+$118K	﹤0.01%	2733
2021 Q2	$125K	Hold	5,251	–	–	﹤0.01%	2813
2021 Q1	$135K	Buy	+5,251	New	+$152K	﹤0.01%	2756
2020 Q4	–	Sell	-1,551	Closed	-$37K	–	2705
2020 Q3	$37K	Buy	+1,551	New	+$41.2K	﹤0.01%	2562

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T. Rowe Price Associates's LPCN Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Lipocine (LPCN) in Q2 2026: 12,266 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #3208 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in LPCN as recently as Q1 2023.

T. Rowe Price Associates first reported a position in LPCN in Q3 2020 and has held it in 11 quarters since. The position peaked at $253K in Q1 2022. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

T. Rowe Price Associates held 12,266 shares of Lipocine worth $32K as of Q2 2026.
Lipocine was a new T. Rowe Price Associates position in Q2 2026.
Lipocine made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3208 holding.
T. Rowe Price Associates first reported a position in Lipocine in Q3 2020 and has held it in 11 quarters since.
T. Rowe Price Associates's Lipocine position peaked at $253K in Q1 2022.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.